Loading…
← CockpitCompetitor Analysis › EMBC Embecta CorporationOpen in the cockpit ↗

Embecta CorporationEMBCCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 95
Mkt cap
$345M
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$5.33M
20-day average traded
Fwd P/E
3.8×
forward earnings
ROIC−WACC
+25.4 pp
WACC 6.2%
Hurdle
-20 pp
Req g minus delivered
Next earnings
13 days
1 Dec 2026
Close · USD$6.09
1D-1.0%
1W-6.7%
1M-5.1%
3M+11.3%
6M+99.0%
YTD-48.7%
1Y-57.4%
ATR %5.2%
Beta0.69
52w lowhigh58.9% off high

What Embecta does

Employees: 1,850

Embecta at a glance

Size Embecta (EMBC) is a United States Health Care company (Medical Specialties) with a market value of $345M, the 2965th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.09 on 18 Nov 2026.

Performance Over six months the shares gained 99.0%, against -15.3% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth Revenue fell 7.6% over the last twelve months (peer median +7.0%); the operating margin is 26.4% (peer median 7.9%).

Valuation It trades at 3.8× forward earnings against a peer median of 18.2× (cheapest of 12).

Price implies For today's price to make sense, revenue must grow about -20% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -20 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 25.4 points above its cost of capital (6.2% WACC).

Short interest Short interest is 10.3% of the free float (30 Oct 2026).

Next results Next results expected around 1 Dec 2026 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026EMBC 183Peer median 85
Six months, rebased to 100: Embecta against the median of its 20 peers (local-currency closes).

Embecta financials

Reported figures in USD; fiscal year ends 2025-09-30. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.02B$1.08B$1.12B$1.12B$1.13B
Revenue growth—-4%0%-1%—
Gross profit$608M$680M$729M$750M$775M
EBITDA$323M$380M$217M$262M$410M
Net income$87.5M$95.4M$78.3M$70.4M$224M
Free cash flow$165M$182M$19.9M$41.2M$389M
Capital expenditure$9.50M$9.30M$15.8M$26.5M$24.0M
Total debt$1.50B$1.45B$1.63B$1.66B$1.65B

Quarterly statements and history in the cockpit →

Embecta competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-20%0%+20%YDESCLTNVBSN688273377740300653301502688338197A1609SBSBWAY3005626748EMBC6-month return →1-month return →
Up and to the right = strong over both horizons. Embecta is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×250×500×750×CLTN688273377740300653197A300753BWAY3005625889EMBCRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Embecta is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%CLTNVBSN6882733777403006533015026883386884681609300753BWAY30056258892041EMBCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Embecta is the large dot.

Embecta competitors and peer comparison

How Embecta compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Embecta against its 20 peers (data as of 18 Nov 2026)
MeasureEMBCPeer medianRank in peer set
1-month return-5.1%-9.8%8th highest of 21
6-month return+99.0%-15.3%2nd highest of 20
Distance from 52-week high-58.9%-42.8%5th lowest of 21
Revenue growth (TTM)-7.6%+7.0%5th lowest of 21
Operating margin26.4%7.9%5th highest of 21
Forward P/E3.8×18.2×cheapest of 12
Growth the price implies (Req g, 7 yrs)-19.9%15.8%least demanding of 16
Growth delivered (Del g)-0.1%+0.4%7th lowest of 16
Hurdle (Req g minus delivered)-19.8 pp+6.1 pp3rd least demanding of 16
ROIC minus cost of capital+25.4 pp+0.6 pp3rd highest of 19
EV / EBITDA5.0×10.2×2nd cheapest of 11
Net debt / EBITDA4.0×-2.1×most indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Embecta EMBCUnited States$345M+99%-8%26%3.8×-19.9%-0.1%
YD Bio YDESUnited States$344M+7%+17%-883%n/an/an/a
COLTENE CLTN.SWSwitzerland$339M-7%-2%8%25.2×-0.3%-0.7%
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%n/a-12.7%-1.3%
Nanjing Medlander Medical Technology 688273.SSChina$337M-47%-12%8%17.5×35.3%+5.2%
BioNote 377740.KSSouth Korea$337M-14%+12%18%14.4×-15.0%-28.5%
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%36.0×18.4%+4.4%
Jiangsu Huayang Intelligent Equipment 301502.SZChina$336M-36%-5%2%n/a34.3%+0.4%
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%16.4×5.7%+3.4%
Tauns Laboratories 197A.TJapan$327M-3%+7%29%16.7×n/an/a
Chemclin Diagnostics 688468.SSChina$327M-24%-10%4%n/a15.8%-4.5%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%n/a-13.1%+36.8%
Stratec SBS.DEGermany$365M+63%-6%4%18.2×19.1%+0.1%
Jiangsu Apon Medical Technology 300753.SZChina$326M-34%-15%-10%862.0×20.0%-5.1%
Shenzhen Bioeasy Biotechnology 300942.SZChina$326M-27%+12%-2%n/an/an/a
CapsoVision CVUnited States$366M+5%+15%-213%n/an/an/a
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%20.3×24.9%+18.8%
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%25.3×-4.2%-6.0%
Japan Eyewear 5889.TJapan$318M-5%+15%32%10.7×-9.4%+20.2%
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%n/an/an/a
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%n/a17.1%+18.1%

Questions

Which companies are Embecta's closest peers?
The cockpit's peer set: YD Bio (YDES), COLTENE (CLTN.SW), IVF HARTMANN (VBSN.SW), Nanjing Medlander Medical Technology (688273.SS), BioNote (377740.KS), Yantai Zhenghai Bio-Tech (300653.SZ), Jiangsu Huayang Intelligent Equipment (301502.SZ), Beijing Succeeder Technology (688338.SS).
Is Embecta expensive compared with its peers?
On forward p/e it trades at 3.8× against a peer median of 18.2×, cheapest of 12 in its peer set. For today's price to make sense, revenue must grow about -20% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -20 pp: the price already allows for a slowdown.
How has Embecta stock performed?
Over six months to 18 Nov 2026 the shares returned +99.0% against -15.3% for the median peer; over one year -57.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.